Novartis Kisqali Cuts Death Risk 19% After Six Years, Data Shows
Trial data presented at the European Society for Medical Oncology congress in Madrid show Kisqali helped extend survival for women with a form of high-risk, early-stage breast cancer.
Story updates
11:35:37 AM UTC
SquawkNews
Novartis announced six-year NATALEE data showing Kisqali plus endocrine therapy cut risk of death by 19.1% vs endocrine therapy alone in high—risk HR+/HER2- early breast cancer, with iDFS benefit rising to 5.3% at six years and no new safety signals.Material DetailsContext by AI AnalystThis is late…